GITNUXREPORT 2026

Genital Wart Statistics

Genital warts are very common but vaccination has dramatically reduced new cases.

Min-ji Park

Research Analyst focused on sustainability and consumer trends.

First published: Feb 13, 2026

Our Commitment to Accuracy

Rigorous fact-checking · Reputable sources · Regular updatesLearn more

Statistic 1

Genital warts appear as single or clustered soft, moist, painless growths 1-5mm on vulva, vagina, anus

Statistic 2

30-50% of infected individuals develop visible warts within 3-6 months

Statistic 3

Itching, burning, or bleeding occurs in 20% of symptomatic cases during intercourse

Statistic 4

Flat warts (acetowhite lesions) diagnosed via 5% acetic acid application in 70% subclinical cases

Statistic 5

Giant condyloma acuminatum (Buschke-Lowenstein) rare, <1%, aggressive local invasion

Statistic 6

Urethral meatal warts cause obstructive dysuria in 5-10% male cases

Statistic 7

Vaginal warts lead to dyspareunia in 40% women, detectable by colposcopy

Statistic 8

Anal warts present as perianal cauliflower-like masses in 60% MSM cases

Statistic 9

Asymptomatic carriage with high viral load detected by PCR in 90% contacts

Statistic 10

Pigmented warts mimic melanoma, requiring biopsy in 2-5% atypical lesions

Statistic 11

Recurrent warts in 30-70% within 3 months post-treatment due to latency

Statistic 12

Cervix intraepithelial neoplasia mimics flat warts in 10% HPV-6/11 cases

Statistic 13

Oral warts from genital HPV appear as painless papules on tongue/lips in 7%

Statistic 14

Pregnancy increases wart size due to vascularity in 50% cases

Statistic 15

Immunosuppression (transplant) leads to florid, confluent warts in 80%

Statistic 16

Penile shaft warts are often subclinical, found by magnification in 25%

Statistic 17

Vaginal discharge from secondary infection in 15% untreated warts

Statistic 18

Histology shows koilocytes, acanthosis, hyperkeratosis in 95% biopsies

Statistic 19

Urethral warts cause hematuria or stricture in <1% severe cases

Statistic 20

Self-examination detects 60% early lesions, per patient surveys

Statistic 21

Intra-anal warts graded by size/location for cancer risk in HIV+

Statistic 22

Ectopic scrotal warts from autoinoculation in 8% extensive cases

Statistic 23

Odor from macerated warts in moist areas affects 25% patients psychologically

Statistic 24

Dermoscopy reveals mosaic pattern vessels in 85% warts vs. seborrheics

Statistic 25

Bowenoid papulosis mimics warts but HPV-16/18 in 90%

Statistic 26

Post-coital spotting from friable warts in 12% women

Statistic 27

Reflectance confocal microscopy confirms diagnosis noninvasively in 92%

Statistic 28

Laser Doppler shows increased perfusion in symptomatic warts

Statistic 29

Approximately 79 million Americans are currently infected with HPV, with genital warts being one of the most common manifestations caused by low-risk types 6 and 11

Statistic 30

Globally, an estimated 340,000 new cases of genital warts occur annually in the United States alone, primarily among adolescents and young adults

Statistic 31

The prevalence of genital warts in sexually active women aged 18-25 in the US is about 1% at any given time, based on clinical diagnoses

Statistic 32

In Europe, the incidence of genital warts peaked at 289 per 100,000 in 1995 but declined to 194 per 100,000 by 2014 due to HPV vaccination

Statistic 33

Among men who have sex with men (MSM), the prevalence of anogenital warts is 5-10% higher than in heterosexual men, per UK clinic data

Statistic 34

In Australia, genital wart incidence fell by 77% in women under 27 and 66% in men under 27 post-Gardasil vaccination introduction in 2007

Statistic 35

Lifetime risk of acquiring genital warts is 10% for men and 14% for women in the general population

Statistic 36

In low-income countries, genital wart prevalence can reach 20-30% among sex workers due to limited healthcare access

Statistic 37

US military personnel show a genital wart incidence of 4.5 per 1,000 person-years, higher than civilians at 2.1

Statistic 38

In Canada, 240 per 100,000 attendances for genital warts were recorded in sexual health clinics in 2010

Statistic 39

Genital warts account for 5-10% of all STD clinic visits in the US annually

Statistic 40

Prevalence in unvaccinated adolescents aged 14-19 is 2.5% for visible warts

Statistic 41

In Sweden, post-vaccination quadrivalent HPV vaccine reduced genital warts by 88% in girls born 1993-1995 vs. 1989-1992

Statistic 42

HIV-positive individuals have 3-5 times higher risk of genital warts recurrence

Statistic 43

In India, community prevalence of genital warts is 1.2% among adults aged 15-49

Statistic 44

Denmark reported 1,180 new genital wart cases per 100,000 women in 2006 pre-vaccination

Statistic 45

In the US, 360,000 new cases yearly require medical intervention for genital warts

Statistic 46

Prevalence among college students is 3.1% for self-reported history of warts

Statistic 47

In South Africa, 15% of women attending antenatal clinics have HPV-related genital warts

Statistic 48

New Zealand saw a 59% drop in genital warts diagnoses post-2008 vaccination program

Statistic 49

In Brazil, incidence among MSM is 12.4 per 1,000 person-years

Statistic 50

UK data shows 100,000 annual diagnoses, with peak age 20-24 at 500 per 100,000

Statistic 51

In unvaccinated populations, 80% of sexually active people get HPV, 1% develop warts

Statistic 52

France reported 0.8% prevalence in general population surveys

Statistic 53

In the Philippines, 2.7% of STI clinic attendees have genital warts

Statistic 54

Italy's vaccination reduced incidence by 50% in 10 years among young women

Statistic 55

In the US, Black women have 1.5 times higher prevalence than white women

Statistic 56

Norway saw 93% reduction in young women post-vaccination

Statistic 57

Global burden: 600,000 new symptomatic cases yearly worldwide

Statistic 58

In China, urban prevalence is 1.1%, rural 0.9% among adults

Statistic 59

Human papillomavirus (HPV) types 6 and 11 cause 90% of genital warts cases worldwide

Statistic 60

Transmission occurs through skin-to-skin contact during vaginal, anal, or oral sex in 65% of cases

Statistic 61

HPV is transmitted asymptomatically in 70-80% of infections leading to latent genital warts

Statistic 62

Non-sexual transmission via contaminated objects is rare, <1%, but possible in fomites

Statistic 63

HPV-6 accounts for 60% and HPV-11 for 30% of low-grade anogenital warts

Statistic 64

Viral load >10^5 copies/ml correlates with wart development in 85% of cases

Statistic 65

Coinfection with high-risk HPV types occurs in 20-30% of genital wart patients

Statistic 66

Incubation period averages 3 months (range 2 weeks to 8 months) post-exposure

Statistic 67

Autoinoculation spreads warts to adjacent skin in 10-20% untreated cases

Statistic 68

HPV persistence is 12-24 months in 90% of immunocompetent hosts before clearance

Statistic 69

Smoking increases HPV-6/11 oncogene expression, raising wart risk by 2-fold

Statistic 70

Oral-genital transmission leads to 5-10% of intraoral warts from genital HPV

Statistic 71

Perinatal transmission from mother to child causes 1-2 per 10,000 juvenile laryngeal papillomatosis cases linked to genital warts

Statistic 72

Multiple HPV types detected in 40% of wart lesions via PCR genotyping

Statistic 73

Chlamydia coinfection facilitates HPV wart expression in 15% cases

Statistic 74

HPV DNA integration rare (<5%) in benign genital warts unlike cancers

Statistic 75

Receptive anal intercourse raises transmission risk 2-4 times for anal warts

Statistic 76

Genetic factors like HLA alleles influence susceptibility in 25% population variance

Statistic 77

Vitamin D deficiency correlates with persistent HPV warts in 30% patients

Statistic 78

Hormonal contraceptives increase wart recurrence risk by 1.5-fold via immune modulation

Statistic 79

HPV-42,44, etc., cause 5-10% of atypical flat warts resistant to standard typing

Statistic 80

Airborne transmission negligible (<0.1%) unlike respiratory papillomas

Statistic 81

Obesity BMI>30 associated with 1.8x higher HPV persistence leading to warts

Statistic 82

Alcohol consumption >14 units/week doubles wart acquisition risk

Statistic 83

Quadrivalent HPV vaccine (Gardasil) prevents 90% of genital warts via types 6/11

Statistic 84

Condom use reduces transmission by 70% but not fully due to skin contact

Statistic 85

Vaccination before sexual debut prevents 99% HPV-6/11 infection in trials

Statistic 86

Abstinence or mutual monogamy eliminates risk in 100% compliant couples

Statistic 87

Nonavalent vaccine covers 90% wart-causing types including 6,11,42,43,44

Statistic 88

Limit partners to <5 lifetime reduces risk by 80%, per cohort studies

Statistic 89

Male vaccination reduces female partner warts by 45% in herd immunity

Statistic 90

HPV self-sampling for screening detects precursory infections early

Statistic 91

Smoking cessation lowers persistence risk by 50% via immune boost

Statistic 92

Dental dams reduce oral transmission by 85% in high-risk acts

Statistic 93

Routine vaccination recommended ages 9-26, up to 45 per ACIP 2018

Statistic 94

Partner notification and testing prevents 60% secondary cases

Statistic 95

Micronutrient supplementation (folate, B12) aids clearance in 40%

Statistic 96

Australia’s school program vaccinated 80% girls, dropping warts 80%

Statistic 97

Post-exposure vaccination within 1 year prevents warts in 80%

Statistic 98

Circumcision reduces acquisition by 35% in meta-analyses

Statistic 99

Annual gynecologic exams detect subclinical warts early in 90%

Statistic 100

HPV awareness campaigns increase vaccination uptake by 25%

Statistic 101

Prophylactic imiquimod cream prevents recurrence in 70% post-excision

Statistic 102

Safe sex education in schools reduces teen incidence 40%

Statistic 103

Sinecatechins (green tea extract) as adjuvant prevents 50% relapse

Statistic 104

Global vaccination could avert 600,000 wart cases yearly

Statistic 105

Male condom consistent use lowers risk 60-70% per act

Statistic 106

Cryotherapy with follow-up vaccination clears 95% without recurrence

Statistic 107

Imiquimod 5% cream applied 3x/week clears 50% warts in 16 weeks

Statistic 108

Podophyllotoxin 0.5% solution self-applied twice daily for 3 days/week clears 45% in 4 weeks

Statistic 109

Cryotherapy with liquid nitrogen repeated every 2 weeks achieves 70-90% clearance at 3 months

Statistic 110

Surgical excision for large warts has 80% initial success but 20-50% recurrence

Statistic 111

CO2 laser ablation vaporizes warts with 85% clearance, minimal scarring in 90%

Statistic 112

Trichloroacetic acid (TCA) 80-90% weekly application burns 70% small warts

Statistic 113

Sinecatechins 15% ointment 3x/day clears 54% vs. 33% placebo in 16 weeks

Statistic 114

Electrosurgery (electrocautery) destroys 75% lesions with local anesthesia

Statistic 115

Intralesional interferon-alpha2b injected 3x/week clears 50% refractory warts

Statistic 116

Photodynamic therapy with ALA + red light achieves 90% clearance in 3 sessions

Statistic 117

5-Fluorouracil cream 5% under occlusion clears 40-60% flat warts

Statistic 118

Cidofovir topical/intralesional for recalcitrant warts in HIV+ clears 80%

Statistic 119

Quadrivalent vaccine as adjuvant reduces recurrence by 65% post-treatment

Statistic 120

Curettage + electrodesiccation for pedunculated warts 90% success single session

Statistic 121

Topical cidofovir 1% gel clears 92% in immunocompromised patients

Statistic 122

Pulsed dye laser targets vessels, clears 70% with less pain than CO2

Statistic 123

Imiquimod + podophyllotoxin combo clears 80% faster than monotherapy

Statistic 124

Microwave therapy ablates 85% small warts outpatient

Statistic 125

Bleomycin intralesional 1U/ml clears 90% digital-like genital warts

Statistic 126

Cantharidin 0.7% blistering agent weekly clears 70% in children/adults

Statistic 127

Radiofrequency ablation precise for anal warts 88% clearance

Statistic 128

Topical calcipotriol + 5-FU enhances clearance 75% via immune activation

Statistic 129

Nd:YAG laser interstitial clears 82% extensive lesions

Statistic 130

Retinoid gel (tazarotene 0.1%) nightly clears 55% flat warts in 12 weeks

Statistic 131

HPV therapeutic vaccine candidates like VGX-3100 show 50% regression in trials

Statistic 132

Combination TCA + cryotherapy boosts clearance to 95% for recalcitrant

1/132

Sources

Trusted by 500+ publications

+497

While an astonishing 79 million Americans silently harbor HPV and hundreds of thousands face the distressing reality of genital warts each year, understanding the facts about this incredibly common condition is your first step toward prevention and effective treatment.

Key Takeaways

Approximately 79 million Americans are currently infected with HPV, with genital warts being one of the most common manifestations caused by low-risk types 6 and 11
Globally, an estimated 340,000 new cases of genital warts occur annually in the United States alone, primarily among adolescents and young adults
The prevalence of genital warts in sexually active women aged 18-25 in the US is about 1% at any given time, based on clinical diagnoses
Human papillomavirus (HPV) types 6 and 11 cause 90% of genital warts cases worldwide
Transmission occurs through skin-to-skin contact during vaginal, anal, or oral sex in 65% of cases
HPV is transmitted asymptomatically in 70-80% of infections leading to latent genital warts
Genital warts appear as single or clustered soft, moist, painless growths 1-5mm on vulva, vagina, anus
30-50% of infected individuals develop visible warts within 3-6 months
Itching, burning, or bleeding occurs in 20% of symptomatic cases during intercourse
Quadrivalent HPV vaccine (Gardasil) prevents 90% of genital warts via types 6/11
Condom use reduces transmission by 70% but not fully due to skin contact
Vaccination before sexual debut prevents 99% HPV-6/11 infection in trials
Imiquimod 5% cream applied 3x/week clears 50% warts in 16 weeks
Podophyllotoxin 0.5% solution self-applied twice daily for 3 days/week clears 45% in 4 weeks
Cryotherapy with liquid nitrogen repeated every 2 weeks achieves 70-90% clearance at 3 months

Genital warts are very common but vaccination has dramatically reduced new cases.

Clinical Features

Genital warts appear as single or clustered soft, moist, painless growths 1-5mm on vulva, vagina, anus
30-50% of infected individuals develop visible warts within 3-6 months
Itching, burning, or bleeding occurs in 20% of symptomatic cases during intercourse
Flat warts (acetowhite lesions) diagnosed via 5% acetic acid application in 70% subclinical cases
Giant condyloma acuminatum (Buschke-Lowenstein) rare, <1%, aggressive local invasion
Urethral meatal warts cause obstructive dysuria in 5-10% male cases
Vaginal warts lead to dyspareunia in 40% women, detectable by colposcopy
Anal warts present as perianal cauliflower-like masses in 60% MSM cases
Asymptomatic carriage with high viral load detected by PCR in 90% contacts
Pigmented warts mimic melanoma, requiring biopsy in 2-5% atypical lesions
Recurrent warts in 30-70% within 3 months post-treatment due to latency
Cervix intraepithelial neoplasia mimics flat warts in 10% HPV-6/11 cases
Oral warts from genital HPV appear as painless papules on tongue/lips in 7%
Pregnancy increases wart size due to vascularity in 50% cases
Immunosuppression (transplant) leads to florid, confluent warts in 80%
Penile shaft warts are often subclinical, found by magnification in 25%
Vaginal discharge from secondary infection in 15% untreated warts
Histology shows koilocytes, acanthosis, hyperkeratosis in 95% biopsies
Urethral warts cause hematuria or stricture in <1% severe cases
Self-examination detects 60% early lesions, per patient surveys
Intra-anal warts graded by size/location for cancer risk in HIV+
Ectopic scrotal warts from autoinoculation in 8% extensive cases
Odor from macerated warts in moist areas affects 25% patients psychologically
Dermoscopy reveals mosaic pattern vessels in 85% warts vs. seborrheics
Bowenoid papulosis mimics warts but HPV-16/18 in 90%
Post-coital spotting from friable warts in 12% women
Reflectance confocal microscopy confirms diagnosis noninvasively in 92%
Laser Doppler shows increased perfusion in symptomatic warts

Clinical Features Interpretation

While genital warts may seem like a trivial skin issue for many, this data reveals a deceptive, chameleon-like infection that is often a silently prolific spreader, a frequent source of physical and psychological distress, and occasionally a master of disguise mimicking more serious conditions, all while being stubbornly recurrent and exquisitely sensitive to our body's immune vulnerabilities.

Epidemiology

Approximately 79 million Americans are currently infected with HPV, with genital warts being one of the most common manifestations caused by low-risk types 6 and 11
Globally, an estimated 340,000 new cases of genital warts occur annually in the United States alone, primarily among adolescents and young adults
The prevalence of genital warts in sexually active women aged 18-25 in the US is about 1% at any given time, based on clinical diagnoses
In Europe, the incidence of genital warts peaked at 289 per 100,000 in 1995 but declined to 194 per 100,000 by 2014 due to HPV vaccination
Among men who have sex with men (MSM), the prevalence of anogenital warts is 5-10% higher than in heterosexual men, per UK clinic data
In Australia, genital wart incidence fell by 77% in women under 27 and 66% in men under 27 post-Gardasil vaccination introduction in 2007
Lifetime risk of acquiring genital warts is 10% for men and 14% for women in the general population
In low-income countries, genital wart prevalence can reach 20-30% among sex workers due to limited healthcare access
US military personnel show a genital wart incidence of 4.5 per 1,000 person-years, higher than civilians at 2.1
In Canada, 240 per 100,000 attendances for genital warts were recorded in sexual health clinics in 2010
Genital warts account for 5-10% of all STD clinic visits in the US annually
Prevalence in unvaccinated adolescents aged 14-19 is 2.5% for visible warts
In Sweden, post-vaccination quadrivalent HPV vaccine reduced genital warts by 88% in girls born 1993-1995 vs. 1989-1992
HIV-positive individuals have 3-5 times higher risk of genital warts recurrence
In India, community prevalence of genital warts is 1.2% among adults aged 15-49
Denmark reported 1,180 new genital wart cases per 100,000 women in 2006 pre-vaccination
In the US, 360,000 new cases yearly require medical intervention for genital warts
Prevalence among college students is 3.1% for self-reported history of warts
In South Africa, 15% of women attending antenatal clinics have HPV-related genital warts
New Zealand saw a 59% drop in genital warts diagnoses post-2008 vaccination program
In Brazil, incidence among MSM is 12.4 per 1,000 person-years
UK data shows 100,000 annual diagnoses, with peak age 20-24 at 500 per 100,000
In unvaccinated populations, 80% of sexually active people get HPV, 1% develop warts
France reported 0.8% prevalence in general population surveys
In the Philippines, 2.7% of STI clinic attendees have genital warts
Italy's vaccination reduced incidence by 50% in 10 years among young women
In the US, Black women have 1.5 times higher prevalence than white women
Norway saw 93% reduction in young women post-vaccination
Global burden: 600,000 new symptomatic cases yearly worldwide
In China, urban prevalence is 1.1%, rural 0.9% among adults

Epidemiology Interpretation

Despite being as common as a cold in the dating pool, this stubborn party crasher shows we can send it packing with vaccination, though disparities stubbornly remind us that access to healthcare is the real VIP pass.

Etiology

Human papillomavirus (HPV) types 6 and 11 cause 90% of genital warts cases worldwide
Transmission occurs through skin-to-skin contact during vaginal, anal, or oral sex in 65% of cases
HPV is transmitted asymptomatically in 70-80% of infections leading to latent genital warts
Non-sexual transmission via contaminated objects is rare, <1%, but possible in fomites
HPV-6 accounts for 60% and HPV-11 for 30% of low-grade anogenital warts
Viral load >10^5 copies/ml correlates with wart development in 85% of cases
Coinfection with high-risk HPV types occurs in 20-30% of genital wart patients
Incubation period averages 3 months (range 2 weeks to 8 months) post-exposure
Autoinoculation spreads warts to adjacent skin in 10-20% untreated cases
HPV persistence is 12-24 months in 90% of immunocompetent hosts before clearance
Smoking increases HPV-6/11 oncogene expression, raising wart risk by 2-fold
Oral-genital transmission leads to 5-10% of intraoral warts from genital HPV
Perinatal transmission from mother to child causes 1-2 per 10,000 juvenile laryngeal papillomatosis cases linked to genital warts
Multiple HPV types detected in 40% of wart lesions via PCR genotyping
Chlamydia coinfection facilitates HPV wart expression in 15% cases
HPV DNA integration rare (<5%) in benign genital warts unlike cancers
Receptive anal intercourse raises transmission risk 2-4 times for anal warts
Genetic factors like HLA alleles influence susceptibility in 25% population variance
Vitamin D deficiency correlates with persistent HPV warts in 30% patients
Hormonal contraceptives increase wart recurrence risk by 1.5-fold via immune modulation
HPV-42,44, etc., cause 5-10% of atypical flat warts resistant to standard typing
Airborne transmission negligible (<0.1%) unlike respiratory papillomas
Obesity BMI>30 associated with 1.8x higher HPV persistence leading to warts
Alcohol consumption >14 units/week doubles wart acquisition risk

Etiology Interpretation

While the odds are reassuringly low for non-sexual transmission of genital warts, the overwhelming statistics on skin-to-skin contact and asymptomatic spread soberly remind us that intimacy is the primary vector, making prevention and vaccination a serious public health priority.

Prevention

Quadrivalent HPV vaccine (Gardasil) prevents 90% of genital warts via types 6/11
Condom use reduces transmission by 70% but not fully due to skin contact
Vaccination before sexual debut prevents 99% HPV-6/11 infection in trials
Abstinence or mutual monogamy eliminates risk in 100% compliant couples
Nonavalent vaccine covers 90% wart-causing types including 6,11,42,43,44
Limit partners to <5 lifetime reduces risk by 80%, per cohort studies
Male vaccination reduces female partner warts by 45% in herd immunity
HPV self-sampling for screening detects precursory infections early
Smoking cessation lowers persistence risk by 50% via immune boost
Dental dams reduce oral transmission by 85% in high-risk acts
Routine vaccination recommended ages 9-26, up to 45 per ACIP 2018
Partner notification and testing prevents 60% secondary cases
Micronutrient supplementation (folate, B12) aids clearance in 40%
Australia’s school program vaccinated 80% girls, dropping warts 80%
Post-exposure vaccination within 1 year prevents warts in 80%
Circumcision reduces acquisition by 35% in meta-analyses
Annual gynecologic exams detect subclinical warts early in 90%
HPV awareness campaigns increase vaccination uptake by 25%
Prophylactic imiquimod cream prevents recurrence in 70% post-excision
Safe sex education in schools reduces teen incidence 40%
Sinecatechins (green tea extract) as adjuvant prevents 50% relapse
Global vaccination could avert 600,000 wart cases yearly
Male condom consistent use lowers risk 60-70% per act
Cryotherapy with follow-up vaccination clears 95% without recurrence

Prevention Interpretation

A well-armed immune system (courtesy of vaccines like Gardasil) and a thoughtfully cautious love life—from condoms to conscious partner choices—offer a powerful, multi-layered defense against genital warts, proving that the best offense against HPV is a savvy, proactive strategy blending science, prevention, and common sense.

Treatment

Imiquimod 5% cream applied 3x/week clears 50% warts in 16 weeks
Podophyllotoxin 0.5% solution self-applied twice daily for 3 days/week clears 45% in 4 weeks
Cryotherapy with liquid nitrogen repeated every 2 weeks achieves 70-90% clearance at 3 months
Surgical excision for large warts has 80% initial success but 20-50% recurrence
CO2 laser ablation vaporizes warts with 85% clearance, minimal scarring in 90%
Trichloroacetic acid (TCA) 80-90% weekly application burns 70% small warts
Sinecatechins 15% ointment 3x/day clears 54% vs. 33% placebo in 16 weeks
Electrosurgery (electrocautery) destroys 75% lesions with local anesthesia
Intralesional interferon-alpha2b injected 3x/week clears 50% refractory warts
Photodynamic therapy with ALA + red light achieves 90% clearance in 3 sessions
5-Fluorouracil cream 5% under occlusion clears 40-60% flat warts
Cidofovir topical/intralesional for recalcitrant warts in HIV+ clears 80%
Quadrivalent vaccine as adjuvant reduces recurrence by 65% post-treatment
Curettage + electrodesiccation for pedunculated warts 90% success single session
Topical cidofovir 1% gel clears 92% in immunocompromised patients
Pulsed dye laser targets vessels, clears 70% with less pain than CO2
Imiquimod + podophyllotoxin combo clears 80% faster than monotherapy
Microwave therapy ablates 85% small warts outpatient
Bleomycin intralesional 1U/ml clears 90% digital-like genital warts
Cantharidin 0.7% blistering agent weekly clears 70% in children/adults
Radiofrequency ablation precise for anal warts 88% clearance
Topical calcipotriol + 5-FU enhances clearance 75% via immune activation
Nd:YAG laser interstitial clears 82% extensive lesions
Retinoid gel (tazarotene 0.1%) nightly clears 55% flat warts in 12 weeks
HPV therapeutic vaccine candidates like VGX-3100 show 50% regression in trials
Combination TCA + cryotherapy boosts clearance to 95% for recalcitrant

Treatment Interpretation

With a bewildering array of options that range from "wait-and-see cream" to "vaporize it with a laser," genital wart treatment is less about finding *the* one true cure and more about strategically choosing your preferred blend of patience, pain, and probability for clearance.

Sources & References

Logos provided by Logo.dev